Home
The Department of Biomedicine

News archive for The Department of Biomedicine

Thomas Arnesen and Harald Barsnes from the Department of Biomedicine are part of a new european consortium in the field of mass spectrometry based proteomics research. The European Union has awarded 10 million Euro.
Cinderella is a tale of being lifted from obscurity to recognition and significance. A review by young researchers at the Department of Biomedicine highlights the importance of the post-translational modifications of actin.
The Retinal Microcircuits Research Group investigates how neurons in the retina communicate to produce vision. In their latest study, they looked outside the conventional neural circuits and found some unexpected receptor molecules in unexpected locations.
Suicide gene therapy of glioblastoma induces an immunosuppressive microenvironment.
One long-standing question in myelin biochemistry was solved, as a new binding partner specific for the large isoform of MAG was identified.
Matrix Biology group leader and CCBIO PI Donald Gullberg recently returned from an inspiring conference in China.
The research laboratory for brain cancer immunology and therapy at the Department of Biomedicine has received the secretary general of the Brain-Tumour Society Rolf Ledal to discuss current and future research projects.
This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.
For the third time, the Faculty of Medicine organized a career day for its PhD candidates. NTNU sent representatives to learn from us.
In an article published in Aftenposten Viten, researcher Marte Innselset Flydal describes how she is planning to develop medicine for children suffering from the rare disease phenylketonuria.
Meg Veruki and Espen Hartveit from the Retinal Microcircuits Research Group at the Department of Biomedicine have been chosen to be the Visionaries of the Quarter for the European Vision Institute.
Researcher's Grand Prix-cadidate Illimar Hugo Rekand is working to keep us healthy. He is investigating new opportunities for making new medicines in a world where antibiotic resistance is an increasing challenge.

Pages